The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Jean-Jacques Kiladjian
Chair
Jean-Jacques Kiladjian is a Professor of Clinical Pharmacology at Université Paris Cité, Paris, FR, and a Consultant Hematologist and Head of the Clinical Investigation Center of Hôpital Saint-Louis, Paris, FR. Professor Kiladjian’s work focuses on clinical research and the development of novel therapeutics for the treatment of patients with myeloproliferative neoplasms (MPN) and myelodysplastic syndromes.
Professor Kiladjian is an active member of many societies, including the European Hematology Association, for which he is co-chair of the Scientific Working Group on MPN. He is also a member of the American Society of Hematology, as well as the European LeukemiaNet, for which he is secretary of the MPN Working Group, and president of the French Intergroup of Myeloproliferative neoplasms.
Filter by content: